ETH Zurich professor Peter Seeberger has been working on a sugar-based malaria vaccine for years. The new test takes him one important step closer to his goal. The malaria pathogen plasmodium falciparum carries poisonous sugar molecules – called GPIs for short – on its surface that are able to be individually identified. Professor See-berger’s research team is now developing a new method that demonstrates that the malaria pathogen’s toxic sugar molecules trigger a specific immune reaction in adults.
Tests show that blood samples taken from adults living in areas of Africa where malaria is endemic contain specific antibodies against particular GPIs. While infection is still possible despite the antibodies, the consequences are less serious. The immune system recognizes the poisonous sugar molecules as foreign bodies and blocks their toxic impact. Not living in high-risk areas, Europeans lack the relevant antibodies. As soon as Europeans are infected with malaria, the number of antibodies increases significantly. Subsequently, there is a direct link between the amount of antibodies and protection against the disease.
This insight is thanks to a novel method for detecting antibodies. Faustin Kamena, a post-doc in Professor Seeberger’s lab, has developed a special chip that can, inexpensively and with minute quantities of blood serum and sugar molecules, determine whether or not someone has formed particular antibodies against various GPIs. To this end, the researchers use the purest possible GPIs. These can be produced synthetically and in large amounts in a laboratory, as the Seeberger team has demonstrated in earlier research.
The new method involves affixing over 64 pads comprising pinpoint dots to glass slides. Every little pad consists of several tiny heaps of different GPIs in varying concentrations. When blood serum is then administered to such a pad, possible antibodies specifically bind to certain sugar molecules. Dyes then reveal to which GPIs the antibodies have attached themselves.
Thanks to the information obtained from the chip, scientists can produce the specific sugar molecules that the immune system has to recognize. The findings on natural re-sistance subsequently acquired are crucial to developing a sugar-based malaria vaccine. This could prove particularly beneficial to children in malaria-infested regions.
The millions of malaria sufferers are primarily infants under the age of five as only adults develop antibodies against the malaria pathogen’s sugars. An infant’s immune system is incapable of recognizing and combating the toxic sugar molecules. Consequently, a new, selective vaccine is now called for. Professor Seeberger states: “This evidence is another important step towards finding a malaria vaccine because we now know which antibodies protect adults.”
Source: Swiss Federal Institute of Technology
Related stories:
Discovery to hasten new malaria treatments, vaccines for children
April 25 is World Malaria Day 2008 and despite the grim statistics out of Africa there’s cause for celebration. Florida State University biologists have discovered an autoimmune-like response in blood drawn from malaria-infected African children that helps to explain why existing DNA-based anti-malaria vaccines have repeatedly failed to protect them.
Experimental vaccine blocks transmission of malaria in mice: study
Researchers at the National Institutes of Health have developed an experimental vaccine that could, theoretically, eliminate malaria from entire geographic regions, by eradicating the malaria parasite from an area's mosquitoes.
Silencing of molecular 'conversation' may help curb severe allergies
Scientists in Sydney have identified a process, a synergistic encounter between two molecules, that may account for the extreme allergic reactions some people experience. By silencing at least one of these molecules, it may be possible to treat allergies.
Crucial factors in lymphoma development and survival discovered
Experiments with new mouse model suggest therapeutic targets
Researchers at National Jewish Medical and Research Center have discovered an important factor in the development of B-cell lymphomas, one of the fastest growing forms of cancer. The B-cell receptor on the surface of B cells can cooperate with the MYC oncogene to accelerate the development of lymphomas. The research team, led by Yosef Refaeli, PhD, Assistant Professor of Pediatrics at National Jewish Medical and Research Center , also showed that disruption of signals from the B-cell receptor can inhibit growth of the tumors. The research is being published in the June 24 issue of the journal,
PLos Biology.
Nanotechnology, biomolecules and light unite to 'cook' cancer cells
Researchers are testing a new way to kill cancer cells selectively by attaching cancer-seeking antibodies to tiny carbon tubes that heat up when exposed to near-infrared light.
Scientists discover a molecular scaffold that guides connections between brain cells
Nonsignaling glial cells can direct synapse formation in the forging of neural networks
Brain cells known as neurons process information by joining into complex networks, transmitting signals to each other across junctions called synapses. But “neurons don’t just connect to other neurons,” emphasizes Z. Josh Huang, Ph.D., “in a lot of cases, they connect to very specific partners, at particular spots.”
Researchers develop new ultrasensitive assay to detect most poisonous substance known
Scientists at City of Hope and the California Department of Public Health have developed a new ultrasensitive assay to detect botulinum neurotoxin. The toxin is one of the most poisonous substances known that can cause life-threatening disease, and is considered a major potential bioterrorism threat agent. The research team’s work is published today in the online journal
PLoS ONE.
Newly refined antibody therapy may be potent treatment for autoimmune diseases
An old, fickle therapy for a variety of autoimmune diseases is getting a makeover, thanks to a decade-long investigation by Rockefeller University researchers. The original treatment, called intravenous immunoglobulin or IVIG, is an amalgam of specific antibodies made from the pooled blood plasma of thousands of healthy donors.